DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft: German Federal Cartel Office approves planned acquisition of RHÖN-KLINIKUM AG by Asklepios Kliniken GmbH & Co. KGaA
DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Key word(s): Offer/Mergers & Acquisitions
RHÖN-KLINIKUM Aktiengesellschaft: German Federal Cartel Office approves planned acquisition of RHÖN-KLINIKUM AG by Asklepios Kliniken GmbH & Co. KGaA
26.05.2020 / 17:25
The issuer is solely responsible for the content of this announcement.
Corporate News
Bad Neustadt a. d. Saale | 26 May 2020
RHÖN-KLINIKUM AG: German Federal Cartel Office approves planned acquisition of RHÖN-KLINIKUM AG by Asklepios Kliniken GmbH & Co. KGaA
RHÖN-KLINIKUM AG is advising that the German Federal Cartel Office has given its approval to the planned acquisition of up to 100 per cent of the interests in, and sole control over the Company by Asklepios Kliniken GmbH & Co. KGaA in the first review phase. This decision creates new legally valid majority relationships amongst the shareholders.
Stephan Holzinger, chairman of the Board of Management of RHÖN-KLINIKUM AG, said: "The decision by the Federal Cartel Office has created the basis for forging new paths at RHÖN-KLINIKUM AG with a new majority shareholder. RHÖN-KLINIKUM AG has an attractive portfolio of hospitals, medical excellence at the university level, innovative care models such as the campus approach, and numerous digitalisation projects that the Board of Management will continue to pursue steadfastly and with firm commitment. We continue to have an optimistic outlook for the future."
For more information on the takeover offer, please refer to the published Statement at www.rhoen-klinikum-ag.com/takeover-offer.
---------------------------------------------------
RHÖN‐KLINIKUM AG is one of the largest healthcare providers in Germany. The hospital Group offers excellent medical care with a direct link to universities and research facilities. Over 860,000 patients are treated every year at the five Group hospitals located in Bad Berka, Bad Neustadt, Frankfurt (Oder), Giessen and Marburg (UKGM) where more than 18,000 employees work. Key elements of the corporate strategy are entry into the promising future market of telemedicine with Medgate Deutschland, the innovative RHÖN Campus approach for cross-sector and future-oriented healthcare delivery in rural areas as well as the steadfast continuation of the gradual digital transformation.
Further information can be found on the Internet at www.rhoen-klinikum-ag.com
Please refer to our website should you need information regarding the subject of the corona virus.
Follow us on www.twitter.com/rhoenklinikumag www.xing.com/companies/rhön-klinikumag www.youtube.com/rhönklinikumag
Contact:
RHÖN-KLINIKUM AG |Head of Corporate Communications and Marketing
Elke Pfeifer
T. +49 9771 65-12110 | [email protected]
RHÖN-KLINIKUM AG | Head of Investor Relations and Treasury
Julian Schmitt
T. +49 9771 65-12250 | [email protected]
RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale
26.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
RHÖN-KLINIKUM Aktiengesellschaft |
|
Salzburger Leite 1 |
|
97616 Bad Neustadt a.d.Saale |
|
Germany |
Phone: |
+49 (0)9771 - 65-0 |
Fax: |
+49 (0)9771 - 97 467 |
E-mail: |
[email protected] |
Internet: |
www.rhoen-klinikum-ag.com |
ISIN: |
DE0007042301 |
WKN: |
704230 |
Indices: |
SDAX |
Listed: |
Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
EQS News ID: |
1055571 |
|
End of News |
DGAP News Service |
1055571 26.05.2020
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
1.211,08 |
1.232,91 |
1.303,90 |
1.360,16 |
1.402,01 |
1.446,09 |
1.463,98 |
EBITDA1,2 |
97,82 |
125,54 |
125,33 |
80,23 |
101,16 |
105,65 |
105,88 |
EBITDA-Marge3 |
8,08 |
10,18 |
9,61 |
5,90 |
7,22 |
7,31 |
|
EBIT1,4 |
38,70 |
64,94 |
56,80 |
10,60 |
30,52 |
36,11 |
40,40 |
EBIT-Marge5 |
3,20 |
5,27 |
4,36 |
0,78 |
2,18 |
2,50 |
2,76 |
Jahresüberschuss1 |
36,74 |
51,19 |
44,48 |
2,46 |
30,23 |
26,94 |
40,17 |
Netto-Marge6 |
3,03 |
4,15 |
3,41 |
0,18 |
2,16 |
1,86 |
2,74 |
Cashflow1,7 |
80,30 |
49,50 |
47,30 |
113,30 |
97,50 |
41,30 |
109,00 |
Ergebnis je Aktie8 |
0,53 |
0,73 |
0,65 |
0,02 |
0,42 |
0,38 |
0,58 |
Dividende8 |
0,22 |
0,29 |
0,00 |
0,00 |
0,00 |
0,15 |
0,35 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: KPMG
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Rhön-Klinikum |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
704230 |
10,900 |
Halten |
729,89 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
18,17 |
28,00 |
0,64 |
18,63 |
KBV |
KCV |
KUV |
EV/EBITDA |
0,58 |
6,70 |
0,50 |
6,30 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
0,15 |
0,00 |
0,00 |
05.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
08.05.2024 |
08.08.2024 |
07.11.2024 |
28.03.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
0,87% |
-2,85% |
9,00% |
-16,15% |
|
|